The University of Southampton
University of Southampton Institutional Repository

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome
Additional chromosomal aberrations occur frequently in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) of childhood. The treatment outcome of these patients is heterogeneous. This study assessed whether such clinical heterogeneity could be partially explained by the presence and characteristics of additional chromosomal abnormalities. Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996. Secondary aberrations were present in 61% of the cases. Chromosomes 9, 22, 7, 14, and 8 were most frequently abnormal. Most (93%) karyotypes were unbalanced. Three main cytogenetic subgroups were identified: no secondary aberrations, gain of a second Ph and/or >50 chromosomes, or loss of chromosome 7, 7p, and/or 9p, while other secondary aberrations were grouped as combinations of gain and loss or others. Of the three main cytogenetic subgroups, the loss group had the worst event-free survival (P=0.124) and disease-free survival (P=0.013). However, statistical significance was not maintained when adjusted for other prognostic factors and treatment. Karyotypic analysis is valuable in subsets of patients identified by molecular screening, to assess the role of additional chromosomal abnormalities and their correlation with clinical heterogeneity, with possible therapeutic implications.
0887-6924
693-702
Heerema, N.A.
6fb2d3a1-988b-46c7-b0e0-6930da02c27e
Harbott, J.
c9419ae3-be8f-4144-9e47-c85a5c1524b6
Galimberti, S.
12f018bb-fa4b-417d-9662-6ead2df9ac53
Camitta, B.M.
25bf6f2f-bd30-446d-b9ad-1a3c044d130c
Gaynon, P.S.
05277ee4-de56-4b98-a60e-8bfb000878f6
Janka-Schaub, G.
edbc9a92-a126-4fd4-8f17-590176310837
Kamps, W.
aaa675ee-869a-471b-829b-eda34266fbd0
Basso, G.
4f8d2943-2e87-4e0f-ab63-0e85ad33b85b
Pui, C.H.
328aaa19-53dd-4e8e-858b-ab5160be1d7d
Schrappe, M.
5d8412b4-1b04-4b91-8244-d2cd9376acd9
Auclerc, M.F.
51b943c3-b296-42de-b100-25d75b173a0b
Carroll, A.J.
5afc8c74-955b-4f2f-8bf9-434eccc651c5
Conter, V.
0c6460ce-f822-45b1-bf58-ad1fdf60d0cd
Harrison, C.J.
9c9f6b47-8bfc-49dd-b156-74539b170291
Pullen, J.
9fc66188-8c6e-4638-9003-43ad9030098b
Raimondi, S.C.
832b2c10-be4d-4428-a81d-e82005d6659d
Richards, S.
231c6be9-3769-47b3-ae97-06ea844e0448
Riehm, H.
7518c4f4-6eab-41d0-bdf0-7e02aedbbc86
Sather, H.N.
87d86c55-668c-4b69-80ec-22ac589b41aa
Shuster, J.J.
923c5166-626b-4c1e-8f49-1f09279a07d5
Silverman, L.B.
0e6635bc-ddd5-44eb-8ff9-1d3a76048096
Valsecchi, M.G.
7f742d26-861f-42c6-baf7-c6ecf60ac023
Arico, M.
367db44c-379e-4cdf-b259-0a4153fc1ab9
Heerema, N.A.
6fb2d3a1-988b-46c7-b0e0-6930da02c27e
Harbott, J.
c9419ae3-be8f-4144-9e47-c85a5c1524b6
Galimberti, S.
12f018bb-fa4b-417d-9662-6ead2df9ac53
Camitta, B.M.
25bf6f2f-bd30-446d-b9ad-1a3c044d130c
Gaynon, P.S.
05277ee4-de56-4b98-a60e-8bfb000878f6
Janka-Schaub, G.
edbc9a92-a126-4fd4-8f17-590176310837
Kamps, W.
aaa675ee-869a-471b-829b-eda34266fbd0
Basso, G.
4f8d2943-2e87-4e0f-ab63-0e85ad33b85b
Pui, C.H.
328aaa19-53dd-4e8e-858b-ab5160be1d7d
Schrappe, M.
5d8412b4-1b04-4b91-8244-d2cd9376acd9
Auclerc, M.F.
51b943c3-b296-42de-b100-25d75b173a0b
Carroll, A.J.
5afc8c74-955b-4f2f-8bf9-434eccc651c5
Conter, V.
0c6460ce-f822-45b1-bf58-ad1fdf60d0cd
Harrison, C.J.
9c9f6b47-8bfc-49dd-b156-74539b170291
Pullen, J.
9fc66188-8c6e-4638-9003-43ad9030098b
Raimondi, S.C.
832b2c10-be4d-4428-a81d-e82005d6659d
Richards, S.
231c6be9-3769-47b3-ae97-06ea844e0448
Riehm, H.
7518c4f4-6eab-41d0-bdf0-7e02aedbbc86
Sather, H.N.
87d86c55-668c-4b69-80ec-22ac589b41aa
Shuster, J.J.
923c5166-626b-4c1e-8f49-1f09279a07d5
Silverman, L.B.
0e6635bc-ddd5-44eb-8ff9-1d3a76048096
Valsecchi, M.G.
7f742d26-861f-42c6-baf7-c6ecf60ac023
Arico, M.
367db44c-379e-4cdf-b259-0a4153fc1ab9

Heerema, N.A., Harbott, J., Galimberti, S., Camitta, B.M., Gaynon, P.S., Janka-Schaub, G., Kamps, W., Basso, G., Pui, C.H., Schrappe, M., Auclerc, M.F., Carroll, A.J., Conter, V., Harrison, C.J., Pullen, J., Raimondi, S.C., Richards, S., Riehm, H., Sather, H.N., Shuster, J.J., Silverman, L.B., Valsecchi, M.G. and Arico, M. (2004) Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia, 18 (4), 693-702. (doi:10.1038/sj.leu.2403324).

Record type: Article

Abstract

Additional chromosomal aberrations occur frequently in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) of childhood. The treatment outcome of these patients is heterogeneous. This study assessed whether such clinical heterogeneity could be partially explained by the presence and characteristics of additional chromosomal abnormalities. Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996. Secondary aberrations were present in 61% of the cases. Chromosomes 9, 22, 7, 14, and 8 were most frequently abnormal. Most (93%) karyotypes were unbalanced. Three main cytogenetic subgroups were identified: no secondary aberrations, gain of a second Ph and/or >50 chromosomes, or loss of chromosome 7, 7p, and/or 9p, while other secondary aberrations were grouped as combinations of gain and loss or others. Of the three main cytogenetic subgroups, the loss group had the worst event-free survival (P=0.124) and disease-free survival (P=0.013). However, statistical significance was not maintained when adjusted for other prognostic factors and treatment. Karyotypic analysis is valuable in subsets of patients identified by molecular screening, to assess the role of additional chromosomal abnormalities and their correlation with clinical heterogeneity, with possible therapeutic implications.

This record has no associated files available for download.

More information

Published date: 2004

Identifiers

Local EPrints ID: 26382
URI: http://eprints.soton.ac.uk/id/eprint/26382
ISSN: 0887-6924
PURE UUID: 14f5dea7-118d-46b4-ab19-13f481272491

Catalogue record

Date deposited: 12 Apr 2006
Last modified: 15 Mar 2024 07:10

Export record

Altmetrics

Contributors

Author: N.A. Heerema
Author: J. Harbott
Author: S. Galimberti
Author: B.M. Camitta
Author: P.S. Gaynon
Author: G. Janka-Schaub
Author: W. Kamps
Author: G. Basso
Author: C.H. Pui
Author: M. Schrappe
Author: M.F. Auclerc
Author: A.J. Carroll
Author: V. Conter
Author: C.J. Harrison
Author: J. Pullen
Author: S.C. Raimondi
Author: S. Richards
Author: H. Riehm
Author: H.N. Sather
Author: J.J. Shuster
Author: L.B. Silverman
Author: M.G. Valsecchi
Author: M. Arico

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×